Sarep­ta snags its part­ner's CSO, Louise Rodi­no-Kla­pac, to lead new gene ther­a­py unit

Putting one more ar­row in its mus­cu­lar dy­s­tro­phy quiver, Sarep­ta has snagged a top ex­ec­u­tive from one of its part­ners to lead the com­pa­ny’s new­ly-cre­at­ed gene ther­a­py unit. Louise Rodi­no-Kla­pac is com­ing on board as vice pres­i­dent of gene ther­a­py.

Rodi­no-Kla­pac is com­ing from Sarep­ta’s part­ner Na­tion­wide Chil­dren’s Hos­pi­tal, where she was head­ing up the lab­o­ra­to­ry for gene ther­a­py re­search for mus­cu­lar dy­s­tro­phies. Her work has in­volved 11 in­ves­ti­ga­tion­al new gene ther­a­py drugs, and six that have reached hu­man tri­als. Sarep­ta is part­nered with the hos­pi­tal on a mi­cro-dy­s­trophin Duchenne gene ther­a­py that got IND clear­ance last No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER